Tuesday, January 19, 2021 12:37:35 PM
Recent ACRS News
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer • PR Newswire (US) • 04/23/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:08:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:04:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:02:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:14:59 PM
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:32:20 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:06:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:24:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:36:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:31:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:29:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:27:54 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/05/2024 09:31:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 12:30:10 PM
- Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review • GlobeNewswire Inc. • 01/16/2024 12:00:00 PM
- Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:47:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:44:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:15:25 PM
- Aclaris Therapeutics Provides Corporate Update • GlobeNewswire Inc. • 12/19/2023 09:01:00 PM
- Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia • GlobeNewswire Inc. • 12/05/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:42:20 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM